Epsilon Healthcare
- Short interest
- 0.01%
- +0.01 pp 30d
- as of 5 June 2023
- Reported shorts
- 22.2K
- Shares on issue
- 300.354M
Epsilon Healthcare (EPN) financials
Results, ratios and statements
Latest result
Half year to 30 Jun 2026 (HY26), figures in AUD, the reporting currency · Company filing, 31 Aug 2026
- Revenue
- $7.6MF (source: Company filing (extracted))vs n/a
- Company filing (extracted), as at 10 Oct 2026
- NPAT
- n/avs n/a
- EPS (basic)
- n/avs n/a
- Rev YoY
- +67.7%FY
- EPS YoY
- n/aTTM
- Company filing (extracted)
Summary of Half Yearly Report and Accounts, 31 Aug 2026
Epsilon Healthcare's half-year revenue surged 123% to $7.59 million, while the net loss narrowed 65% to $0.73 million, with EBITDA turning positive at $0.25 million. No dividend was declared. The company highlighted strong growth in its CDMO and pharmacy segments and expects continued momentum.
Automated summary of the filing; the filing itself is the record.
Key ratios
Year to 31 Dec 2025 (FY); balance sheet at 31 Dec 2025; prices to 15 Oct 2026
- Gross margin
- 61.3%
- Operating margin
- −25.3%
- Net margin
- −13.6%
- FCF margin
- −35.1%
- ROE
- n/a
- ROA
- −9.0%
- FCF conversion
- n/a
- Net debt (excl. leases)
- $4.6M
- Net debt / EBITDA
- n/a
- Current ratio
- 1.2×
- Interest cover
- −2.6×
- Cash dividends paid / net profit
- n/a
- Market cap
- $10.6M
- P/E
- n/a
- P/B
- 5.6×
Ratios use the reporting currency (AUD); market cap is in AUD. Source: Yahoo Finance, as at 14 Oct 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|
| Revenue | $9.4M | $5.6M | $6.7M | $7.1M |
| Gross profit | $5.8M | $4.3M | $5.0M | $725.8K |
| Operating income | −$2.4M | −$4.9M | −$2.4M | −$8.4M |
| EBITDA | −$987.1K | −$3.1M | −$1.4M | −$10.2M |
| EBIT | −$1.3M | −$4.5M | −$2.8M | −$12.1M |
| Interest expense | $899.6K | $1.1M | $477.0K | $577.5K |
| Pretax income | −$2.2M | −$5.6M | −$3.3M | −$12.7M |
| Tax | −$966.8K | −$133.4K | −$2.2M | $0 |
| NPAT | −$1.3M | −$5.5M | −$1.1M | −$12.7M |
| Net interest income | −$1.1M | −$1.2M | −$515.2K | −$677.6K |
| EPS basic | −$0.003 | −$0.016T (source: Derived: trailing 12 months at year end) | −$0.004 | −$0.066 |
| EPS diluted | −$0.003 | −$0.016T (source: Derived: trailing 12 months at year end) | −$0.004 | −$0.066 |
| Shares | 379.1M | 345.4M | 345.4M | 193.3M |
- Derived: trailing 12 months at year end
Financial reports
The company's own filings, newest first
- Update to Appendix 4C Managing Director LoanQuarterly Report25 Sep 2026via asx_announcements
- Half Yearly Report and AccountsHalf Year Results31 Aug 2026via asx_announcements
Figures above come from this filing
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Jul 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Apr 2026via asx_announcements
- Annual Report to shareholdersAnnual Report31 Mar 2026via asx_announcements
- Preliminary Final ReportAnnual Results27 Feb 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report28 Jan 2026via asx_announcements
- Half Yearly Report and AccountsHalf Year Results16 Dec 2025via asx_announcements
- Annual Report to shareholdersAnnual Report19 Nov 2025via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report7 Nov 2025via asx_announcements
Showing 10 of 23 reports